News

Antony Mattessich Joins Amphista Therapeutics as CEO

Antony Mattessich Joins Amphista Therapeutics as CEO

Amphista Therapeutics Welcomes New Chief Executive Officer

Amphista Therapeutics has made a significant advancement by appointing Antony Mattessich as its new Chief Executive Officer (CEO). This decision is anticipated to accelerate the company’s growth, especially in the development of its innovative Targeted Glue™ protein degraders, which are on the verge of entering clinical trials.

Exciting Milestones and Future Growth

The appointment of Mattessich follows an impressive year for Amphista in 2024. The company recently celebrated three major milestones that underscore its pioneering capabilities: demonstrating in vivo efficacy, successfully targeting and degrading proteins within the central nervous system (CNS), and revealing a novel mechanism of action for protein degradation.

Background of Antony Mattessich

Antony Mattessich comes to Amphista with a wealth of experience, having successfully guided numerous programs from initial discovery through clinical development and into successful commercialization. Over his career, he has raised more than $750 million to support various biotechnology ventures. Prior to joining Amphista, he was the President and CEO of Ocular Therapeutix, a Nasdaq-listed company, where he played a key role in developing treatments for conditions like Wet Age-Related Macular Degeneration.

Mattessich's Vision for Amphista

Upon his appointment, Mattessich shared his excitement about his new role at Amphista. He stated, "2024 is a pivotal year for Amphista, and I am thrilled to be part of a company with such unique technology in the targeted protein degradation sector at this exciting stage of its development. My goal will be to evolve Amphista's portfolio to transform innovative research into groundbreaking treatments that enhance patients' lives."

Support from the Chairman

Joshua Brumm, Chairman of Amphista's Board of Directors, echoed Mattessich's enthusiasm, saying, "Antony’s extensive experience in drug development, combined with his insights into capital markets, aligns perfectly with our strategy to advance our leading assets into clinical trials following this year’s compelling new data on in vivo efficacy and CNS activity. We are excited to welcome Antony during such a transformative time for Amphista."

Recent Scientific Progress

Earlier in 2024, Amphista announced the success of its next-generation bifunctional protein degraders. Additionally, the company introduced a new mechanism of action for degrading BRD9, a promising target in oncology. This innovative strategy sets itself apart from traditional cereblon- or VHL-based technologies, showcasing Amphista’s commitment to advancing its groundbreaking targeted protein degradation (TPD) medicines.

About Amphista Therapeutics

Amphista Therapeutics is committed to transforming treatment options for patients facing severe conditions, including cancer and neurodegenerative disorders, by advancing next-generation targeted protein degradation therapies. Utilizing proprietary warhead chemistry and mechanistic expertise, Amphista is developing bifunctional Targeted Glue® agents with exceptional properties. This innovative approach not only aims to create first-or-best-in-class drugs but also seeks to expand the application of TPD therapies beyond traditional methods. The company was founded as a spin-out from the University of Dundee, driven by Professor Alessio Ciulli's expertise, and is supported by prominent investors and strategic partners.

For More Information

If you have any inquiries, please contact:

Amphista Therapeutics
John Goodall
Email: info@amphista.com

ICR Consilium
Amber Fennell, Namrata Taak, Emily Johnson
Email: amphista@consilium-comms.com
Tel: +44 (0)20 3709 5813

Frequently Asked Questions

What is Amphista Therapeutics?

Amphista Therapeutics is a biopharmaceutical company dedicated to developing next-generation targeted protein degradation therapies to address challenging diseases.

Who is Antony Mattessich?

Antony Mattessich is the newly appointed CEO of Amphista Therapeutics, bringing extensive experience in drug development and company leadership.

What significant achievements has Amphista made in 2024?

In 2024, Amphista successfully demonstrated in vivo efficacy, targeted protein degradation in the CNS, and introduced new mechanisms for its therapies.

What technologies does Amphista employ?

Amphista utilizes proprietary warhead chemistry to develop bifunctional Targeted Glue® agents aimed at enhancing the effectiveness of TPD treatments.

How can I learn more about Amphista's developments?

For more information, you can visit Amphista's official website or reach out to their communication team directly.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 86

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 103

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Midea's Cooling Systems Take Center Stage at DCW ME

Updated Category News Views 69

AI Surge Demands Cooler Solutions Alright, who'd guess that data centers would feel the heat—literally—like a welder's furnace in Abu Dhabi? As AI demand burns hotter across the Middle East, data centers are sweating it out against 50°C-plus temperatures. We're talking about some serious pressure on traditional cooling methods that just can’t cut it anymore....

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 207

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 255

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 0

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 41

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
TIER IV Simplifies Autonomous Driving with CARLA 1.0

Updated Category News Views 63

No More Detours in Autonomous Development Ever messed with a puzzle that just won't fit until suddenly, it clicks? That's what TIER IV just pulled off with their latest work on CARLA 1.0, the open-source simulator. There's no more mucking about with that separate Python-based bridge to get things communicating—now we're talking native Autoware support. A direct line to...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 63

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 291

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading

Top 5 Most Recently Viewed Articles

Lockheed Martin F-35 Production: Secretary's Inspiring Visit

Updated Category News Views 133

Secretary Visits Lockheed Martin's F-35 Production Facility Lockheed Martin (NYSE: LMT) proudly hosted the Secretary of War Pete Hegseth at its F-35 Lightning II production facility. This important visit highlighted the company's pivotal role in transforming defense acquisition processes. It also emphasized Lockheed Martin's dedication to delivering essential capabilities...

Continue Reading
OneAmerica Financial Foundation Empowers Caregiving Awareness

Updated Category News Views 220

OneAmerica Financial Foundation Supports Vital Caregiving Documentary The OneAmerica Financial Foundation has embarked on a significant journey by sponsoring an enlightening documentary titled "Caregiving." This compelling film delves into the experiences of caregivers, both professional and personal, across the United States. The documentary, narrated by Emmy...

Continue Reading
Multiconsult's Q2 2026: Profitability Rebounds

Updated Category News Views 26

Multiconsult's Financial Figures Take a Turn for the Better Times are looking up for Multiconsult ASA, a solid engineering firm based in Oslo. Their performance in the second quarter of 2026 spawned a tale of boosted revenues and healthier profitability. The crew isn't just resting on its laurels, as they're plugged into strategies that are set to carry them beyond 2026....

Continue Reading
KFC Revamps Menu with Original Honey BBQ and Classic Deals

Updated Category News Views 300

KFC's Exciting Revival: The Return of Iconic Flavors KFC has taken a bold step forward in its comeback era, reintroducing beloved menu items that fans have been eagerly awaiting. This time, the spotlight shines on the return of the highly sought-after Original Honey BBQ flavor. This mouthwatering sauce, which first won hearts in the late 1990s, will be back on October...

Continue Reading
Maxeon Solar Technologies Reports Financial Results for 2024

Updated Category News Views 262

Maxeon Solar Technologies Unveils Financial Outcomes for 2024 Maxeon Solar Technologies, Ltd. (NASDAQ: MAXN) has recently shared its financial results for the fourth quarter and entire fiscal year 2024, highlighting revenue reaching an impressive $509 million. The company faced significant challenges due to restrictions imposed by U.S. Customs and Border Protection (CBP)...

Continue Reading